Published in Ann Surg on June 01, 1995
Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg (1997) 8.86
Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol (2010) 5.07
Importance of hospital volume in the overall management of pancreatic cancer. Ann Surg (1998) 4.19
Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg (2007) 4.09
Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg (1997) 3.90
Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell (2011) 3.47
Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg (2003) 3.13
Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst (2010) 3.08
Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg (1998) 2.60
Genetic progression in the pancreatic ducts. Am J Pathol (2000) 2.58
Adenocarcinoma of the ampulla of Vater. A 28-year experience. Ann Surg (1997) 2.53
Distal pancreatectomy: risk factors for surgical failure in 302 consecutive cases. Ann Surg (2007) 2.51
Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short-term outcome. Ann Surg (1999) 2.36
Fluorescence-guided surgery allows for more complete resection of pancreatic cancer, resulting in longer disease-free survival compared with standard surgery in orthotopic mouse models. J Am Coll Surg (2012) 2.24
Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg (1997) 2.00
Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg (2007) 1.85
Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br J Cancer (2005) 1.71
Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut (2007) 1.68
Pancreaticoduodenectomy. Does it have a role in the palliation of pancreatic cancer? Ann Surg (1996) 1.67
Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP). HPB (Oxford) (2009) 1.67
A systematic review and meta-analysis of pylorus-preserving versus classical pancreaticoduodenectomy for surgical treatment of periampullary and pancreatic carcinoma. Ann Surg (2007) 1.55
Complications of pancreatic surgery. HPB (Oxford) (2005) 1.54
Photodynamic therapy for cancer of the pancreas. Gut (2002) 1.51
Identifying molecular markers for the early detection of pancreatic neoplasia. Semin Oncol (2007) 1.49
HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinoma. Dig Dis Sci (2008) 1.45
Dramatic Survival Benefit Related to R0 Resection of Pancreatic Adenocarcinoma in Patients With Tumor ≤25 mm in Size and ≤1 Involved Lymph Nodes. Clin Transl Gastroenterol (2013) 1.43
A decision model of therapy for potentially resectable pancreatic cancer. J Surg Res (2011) 1.40
A prospective, randomized, double-blind, placebo controlled trial on the efficacy of ethanol celiac plexus neurolysis in patients with operable pancreatic and periampullary adenocarcinoma. J Am Coll Surg (2014) 1.37
The prognostic significance of lymph node metastasis and intrapancreatic perineural invasion in pancreatic cancer after curative resection. Surg Today (1999) 1.37
Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist? Langenbecks Arch Surg (2004) 1.34
Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery (2011) 1.32
Evidence-based pancreatic head resection for pancreatic cancer and chronic pancreatitis. Ann Surg (2002) 1.29
Preoperative lymphocyte count as a prognostic factor in resected pancreatic ductal adenocarcinoma. HPB (Oxford) (2007) 1.26
Fluorescence-guided surgery with a fluorophore-conjugated antibody to carcinoembryonic antigen (CEA), that highlights the tumor, improves surgical resection and increases survival in orthotopic mouse models of human pancreatic cancer. Ann Surg Oncol (2014) 1.25
Stool DNA testing for the detection of pancreatic cancer: assessment of methylation marker candidates. Cancer (2011) 1.20
Pancreatic cancer and the FAMMM syndrome. Fam Cancer (2007) 1.13
Tumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation. Br J Cancer (2010) 1.12
Redefining resection margin status in pancreatic cancer. HPB (Oxford) (2009) 1.12
Circulating microRNAs in Pancreatic Juice as Candidate Biomarkers of Pancreatic Cancer. J Cancer (2014) 1.09
Fluorescence-guided surgery and fluorescence laparoscopy for gastrointestinal cancers in clinically-relevant mouse models. Gastroenterol Res Pract (2013) 1.04
Prognostic implication of para-aortic lymph node metastasis in resectable pancreatic cancer. World J Surg (2007) 1.04
Asymptomatic pancreatic cystic neoplasms: maximizing survival and quality of life using Markov-based clinical nomograms. Gastroenterology (2009) 1.04
Advances in the treatment of pancreatic cancer: limitations of surgery and evaluation of new therapeutic strategies. Surg Today (2009) 1.03
Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma. Cancer (2013) 1.03
Prospective, randomized trial on the effect of cyclic versus continuous enteral nutrition on postoperative gastric function after pylorus-preserving pancreatoduodenectomy. Ann Surg (1997) 1.02
A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma. HPB (Oxford) (2012) 1.02
Pancreaticoduodenectomy with en bloc portal vein resection for pancreatic carcinoma with suspected portal vein involvement. World J Surg (2004) 1.02
The investigation of 125I seed implantation as a salvage modality for unresectable pancreatic carcinoma. J Exp Clin Cancer Res (2013) 0.99
Pathomorphological and histological prognostic factors in curatively resected ductal adenocarcinoma of the pancreas. Surg Today (2000) 0.99
Pancreatic fistula after pancreaticoduodenectomy: the conservative treatment of choice. HPB (Oxford) (2009) 0.99
Re-evaluating the impact of tumor size on survival following pancreaticoduodenectomy for pancreatic adenocarcinoma. J Surg Oncol (2011) 0.99
Vascular reconstruction during pancreatoduodenectomy for ductal adenocarcinoma of the pancreas improves resectability but does not achieve cure. World J Surg (2010) 0.98
Multi-institutional analysis of pancreatic adenocarcinoma demonstrating the effect of diabetes status on survival after resection. HPB (Oxford) (2012) 0.98
Pancreatic cancer--low survival rates. Dtsch Arztebl Int (2008) 0.98
Benefits of specialisation in the management of pancreatic cancer: results of a Scottish population-based study. Br J Cancer (2004) 0.98
Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival. J Cancer Res Clin Oncol (2005) 0.97
Intraoperative ultrasound-guided iodine-125 seed implantation for unresectable pancreatic carcinoma. J Exp Clin Cancer Res (2009) 0.97
Adjuvant therapy in pancreatic cancer. World J Gastroenterol (2001) 0.97
Role of radical antegrade modular pancreatosplenectomy for adenocarcinoma of the body and tail of the pancreas. World J Surg (2014) 0.96
Postoperative complications and overall survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. J Surg Oncol (2015) 0.96
Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer. World J Gastroenterol (2008) 0.96
Advances in the Genetic Screening, Work-up, and Treatment of Pancreatic Cancer. Curr Treat Options Gastroenterol (2004) 0.96
Longterm survival after pancreaticoduodenectomy for periampullary adenocarcinomas. HPB (Oxford) (2013) 0.94
Borderline resectable pancreatic cancer: definitions and management. World J Gastroenterol (2014) 0.92
Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma. Cochrane Database Syst Rev (2014) 0.92
Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer. Radiat Oncol (2013) 0.91
Analysis of long-term survivors after surgical resection for invasive pancreatic cancer. HPB (Oxford) (2005) 0.91
Does multidetector-row CT eliminate the role of diagnostic laparoscopy in assessing the resectability of pancreatic head adenocarcinoma? Surg Endosc (2004) 0.90
Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma. J Gastroenterol (2009) 0.90
Long-term survival and prognostic indicators in small (<or=2 cm) pancreatic cancer. Pancreatology (2008) 0.90
Pancreatic cancer surgery: past, present, and future. Chin J Cancer Res (2015) 0.89
Palliative surgical management of patients with unresectable pancreatic adenocarcinoma: trends and lessons learned from a large, single institution experience. J Gastrointest Surg (2011) 0.89
Adjuvant chemoradiotherapy after pancreatic resection for invasive carcinoma associated with intraductal papillary mucinous neoplasm of the pancreas. Int J Radiat Oncol Biol Phys (2009) 0.89
Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with resectable pancreatic cancer. Yonsei Med J (2013) 0.89
Prognostic significance of pre-operative C-reactive protein and the neutrophil-lymphocyte ratio in resectable pancreatic cancer: a systematic review. HPB (Oxford) (2014) 0.89
Management of remnant pancreatic stump fto prevent the development of postoperative pancreatic fistulas after distal pancreatectomy: current evidence and our strategy. Surg Today (2012) 0.89
Proteasome inhibitor MG132 inhibits angiogenesis in pancreatic cancer by blocking NF-kappaB activity. Dig Dis Sci (2009) 0.88
Upregulated SMAD3 promotes epithelial-mesenchymal transition and predicts poor prognosis in pancreatic ductal adenocarcinoma. Lab Invest (2014) 0.88
New DNA Methylation Markers for Pancreatic Cancer: Discovery, Tissue Validation, and Pilot Testing in Pancreatic Juice. Clin Cancer Res (2015) 0.87
Can K-ras codon 12 mutations be used to distinguish benign bile duct proliferations from metastases in the liver? A molecular analysis of 101 liver lesions from 93 patients. Am J Pathol (1997) 0.87
Surgical palliation in patients with pancreatic cancer. Langenbecks Arch Surg (2006) 0.87
Preoperative body composition is influenced by the stage of operable pancreatic adenocarcinoma but does not predict survival after Whipple's procedure. HPB (Oxford) (2010) 0.87
Effective endovascular stenting of malignant portal vein obstruction in pancreatic cancer. HPB Surg (2009) 0.87
Pancreaticoduodenectomy: volume is not associated with outcome within an academic health care system. HPB Surg (2008) 0.86
Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. Gastroenterology (2015) 0.86
Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer. World J Gastroenterol (2007) 0.86
Risk factors for pancreatic adenocarcinoma and prospects for screening. Gastroenterol Hepatol (N Y) (2010) 0.86
Strategies for early detection of resectable pancreatic cancer. World J Gastroenterol (2014) 0.86
Prognostic analysis of patients with pancreatic head adenocarcinoma less than 2 cm undergoing resection. World J Gastroenterol (2009) 0.86
Validation of a prognostic nomogram in patients undergoing resection for pancreatic ductal adenocarcinoma in a UK tertiary referral centre. HPB (Oxford) (2008) 0.85
Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin. Br J Cancer (2000) 0.85
Image-guided intensity-modulated radiotherapy for pancreatic carcinoma. Gastrointest Cancer Res (2007) 0.85
Impact of reconstruction methods on outcome of pancreatoduodenectomy in pancreatic cancer patients. World J Surg (2005) 0.85
Implementation of an enhanced recovery programme following pancreaticoduodenectomy. HPB (Oxford) (2012) 0.84
Impact of reconstruction methods and pathological factors on survival after pancreaticoduodenectomy. South Asian J Cancer (2013) 0.84
Clinical and pathologic prognostic factors for curative resection for pancreatic cancer. HPB (Oxford) (2008) 0.84
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg (1985) 7.14
Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg (1990) 7.04
Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg (1993) 6.15
The effects of regionalization on cost and outcome for one general high-risk surgical procedure. Ann Surg (1995) 5.95
One hundred and forty-five consecutive pancreaticoduodenectomies without mortality. Ann Surg (1993) 5.87
The advantages of bypass operations over radical pancreatoduodenectomy in the treatment of pancreatic carcinoma. Surg Gynecol Obstet (1970) 5.59
Improved hospital morbidity, mortality, and survival after the Whipple procedure. Ann Surg (1987) 5.58
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet (1994) 4.63
Effect of blood transfusions on colonic malignancy recurrent rate. Lancet (1982) 4.23
Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg (1991) 3.88
Adenocarcinoma of the pancreas: a statistical analysis of biliary bypass vs Whipple resection in good risk patients. Ann Surg (1975) 3.33
p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res (1994) 2.80
The surgical treatment of pancreatic carcinoma. Surgery (1985) 2.57
Pylorus-preserving versus standard pancreatico-duodenectomy: an analysis of 110 pancreatic and periampullary carcinomas. Br J Surg (1992) 2.54
Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res (1994) 2.26
Collective review of small carcinomas of the pancreas. Ann Surg (1986) 2.24
Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann Surg (1993) 2.15
Allelotype of pancreatic adenocarcinoma. Cancer Res (1994) 2.11
Regional pancreatectomy for cancer of the pancreas, ampulla, and other related sites. Tumor staging and results. Ann Surg (1984) 2.03
Pancreatoduodenectomy with pyloric preservation for carcinoma of the pancreas: a cautionary note. Surgery (1989) 1.92
Breast cancer survival and perioperative blood transfusion. Surgery (1989) 1.85
Radical pancreatectomy for ductal cell carcinoma of the head of the pancreas. Cancer (1989) 1.71
Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A Phase II Study. Cancer (1993) 1.69
Clinical highlights from the National Cancer Data Base: 1994. CA Cancer J Clin (1994) 1.58
Pancreatic cancer cell DNA content correlates with long-term survival after pancreatoduodenectomy. Ann Surg (1991) 1.55
Surgical curability and prognosis for standard versus extended resection for T1 carcinoma of the pancreas. Surg Gynecol Obstet (1992) 1.55
Pylorus preserving pancreatoduodenectomy: an overview. Br J Surg (1990) 1.48
Perioperative blood transfusions and cancer recurrence. J Clin Oncol (1988) 1.29
Pancreatoduodenectomy for resectable malignant periampullary tumors. Surg Gynecol Obstet (1983) 1.26
Is the long-term survival rate improved by preoperative irradiation prior to Whipple's procedure for adenocarcinoma of the pancreatic head? Arch Surg (1994) 1.24
Factors influencing survival after resection of pancreatic cancer. A DNA analysis and a histomorphologic study. Cancer (1994) 1.23
Managing unsuspected tumor invasion of the superior mesenteric-portal venous confluence during pancreaticoduodenectomy. Am J Surg (1994) 1.21
Intraoperative radiation therapy following pancreaticoduodenectomy. Ann Surg (1993) 1.21
Pancreaticoduodenectomy for malignant pancreatic and periampullary neoplasms in elderly patients. Am J Surg (1991) 1.20
Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch Surg (1993) 1.19
Surgical indication and significance of portal vein resection in biliary and pancreatic cancer. Surgery (1991) 1.18
Clinical experience with regional pancreatectomy for adenocarcinoma of the pancreas. Arch Surg (1989) 1.16
Postprandial plasma gastrin and secretin concentrations after a pancreatoduodenectomy. A comparison between a pylorus-preserving pancreatoduodenectomy and the Whipple procedure. Ann Surg (1989) 1.05
Gastric emptying and enterogastric reflux after conservative and conventional pancreatoduodenectomy. Surgery (1993) 1.04
Evaluation of DNA nuclear pattern as a prognostic determinant in resected pancreatic ductal adenocarcinoma. Ann Surg (1992) 1.03
Pylorus preserving pancreatoduodenectomy versus Whipple procedure for adenocarcinoma of the head of the pancreas. HPB Surg (1989) 0.87
Arguments against radical (extended) resection for adenocarcinoma of the pancreas. Adv Surg (1994) 0.86
A comparison of flow cytometric and absorption cytometric DNA values as prognostic indicators for pancreatic carcinoma. Cancer (1993) 0.86
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med (2000) 12.34
DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (1996) 11.13
Gene expression profiles in normal and cancer cells. Science (1997) 9.65
Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg (1997) 8.86
Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg (2001) 8.34
Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol (2001) 6.30
Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med (2000) 6.27
The effects of regionalization on cost and outcome for one general high-risk surgical procedure. Ann Surg (1995) 5.95
One hundred and forty-five consecutive pancreaticoduodenectomies without mortality. Ann Surg (1993) 5.87
Improved hospital morbidity, mortality, and survival after the Whipple procedure. Ann Surg (1987) 5.58
Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg (1996) 5.42
Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology (2000) 5.40
Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med (1995) 5.10
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet (1994) 4.63
Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res (1997) 4.54
A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. Ann Surg (1995) 4.24
Importance of hospital volume in the overall management of pancreatic cancer. Ann Surg (1998) 4.19
Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res (2001) 4.19
Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg (1997) 3.90
Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg (1991) 3.88
Decreased morbidity and mortality after pancreatoduodenectomy. Am J Surg (1986) 3.81
Clinical prediction rule for pulmonary infiltrates. Ann Intern Med (1990) 3.81
Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res (2000) 3.74
DPC4 gene in various tumor types. Cancer Res (1996) 3.74
Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med (2000) 3.70
Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res (1996) 3.60
K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol (1993) 3.56
Surgical rates and operative mortality for open and laparoscopic cholecystectomy in Maryland. N Engl J Med (1994) 3.53
Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant (1996) 3.51
Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med (1995) 3.31
Reduced postoperative hospitalization after laparoscopic cholecystectomy. Br J Surg (1991) 3.30
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol (2001) 3.27
Does preoperative percutaneous biliary drainage reduce operative risk or increase hospital cost? Ann Surg (1985) 3.19
Erythromycin accelerates gastric emptying after pancreaticoduodenectomy. A prospective, randomized, placebo-controlled trial. Ann Surg (1993) 3.17
Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res (1997) 3.17
The use of RNAs complementary to specific mRNAs to regulate the expression of individual bacterial genes. Cell (1984) 3.15
Pyogenic hepatic abscess. Changing trends over 42 years. Ann Surg (1996) 3.13
Distal pancreatectomy: indications and outcomes in 235 patients. Ann Surg (1999) 3.09
The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res (2001) 3.02
Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. Ann Surg (2000) 2.94
Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst (2001) 2.93
Selective nonoperative management of contained intrathoracic esophageal disruptions. Ann Thorac Surg (1979) 2.90
Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res (1998) 2.89
p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res (1997) 2.88
p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res (1994) 2.80
Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity. Ann Surg (2001) 2.80
Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer (1999) 2.66
Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis. Cancer Res (2001) 2.65
Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation. Am J Pathol (2000) 2.63
Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg (1998) 2.60
Chronic pancreatic ascites and pancreatic pleural effusions. Gastroenterology (1978) 2.60
Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol (1999) 2.59
Adenocarcinoma of the ampulla of Vater. A 28-year experience. Ann Surg (1997) 2.53